Effect of Personalized Hemodynamic Management Based on Serum Renin Concentration on Acute Kidney Injury Progression in Patients With Shock: a Randomized Controlled Trial.
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 800
- 试验地点
- 5
- 主要终点
- A composite of mortality or AKI progression at 30 days after randomization.
研究概览
简要总结
Shock is a major risk factor for mortality among patients admitted to intensive care units (ICUs). Since various hemodynamic strategies uniformly delivered to patients with shock have failed to improve clinically relevant outcomes, individualized approaches for shock supported by robust evidence are required. This study will be a prospective, multicenter, parallel-group, single-blind, randomized controlled trial. The investigators will randomly assign 800 critically ill patients requiring norepinephrine infusion to the renin-guided or usual care groups. The investigators hypothesize that renin-guided hemodynamic management, compared to usual care, can reduce a composite of mortality and acute kidney injury (AKI) progression in patients requiring vasopressor support.
详细描述
Shock is a common cause of death among patients admitted to intensive care units. Acute kidney injury (AKI) frequently occurs in patients with shock (3, 4). Maintaining adequate perfusion pressure and oxygen delivery is crucial in the hemodynamic management of shock (5). Several randomized controlled trials have evaluated the effect of various hemodynamic protocols treating shock patients with a "one size fits all" approach. However, such protocols did not reduce mortality (6-8). The task force of the surviving sepsis campaign identified the personalization of sepsis resuscitation as a research priority (9). Moreover, a large RCT showed that personalizing blood pressure targets reduced the risk of postoperative organ dysfunction in patients undergoing major surgery (10). These findings suggest that applying individualized hemodynamic strategy may optimize shock treatment and potentially improve outcomes (11).
Recent studies have investigated renin as a novel marker of tissue hypoperfusion in critically ill patients. While serum lactate level has been the most common and validated marker for tissue hypoperfusion (12), several studies are now suggesting that renin may predict mortality better than lactate in critically ill patients (13, 14). Notably, relative renin increase is associated with adverse clinical outcomes and shock reversal has been shown to decrease renin concentration (15).
The investigators aim to perform the Randomized Evaluation of persoNalized hemodynamIc maNagement based on serum renin concentration (RENIN) trial to test the hypothesis that renin-guided hemodynamic management can reduce a composite of mortality and acute kidney injury (AKI) progression during the hospital stay in patients requiring vasopressors compared with usual care.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
盲法说明
Single blind trial. Participants will be blinded to treatment allocation.
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •≥18 years old
- •Admitted to an intensive care unit (ICU)
- •Requiring norepinephrine infusion at any dose to maintain a mean arterial pressure (MAP) of ≥65 mmHg after initial fluid resuscitation
- •Expected to stay in the ICU for at least 24 hours
- •Written informed consent from the patient him-/herself or the patient's next of kin as requested by the ethics committee.
排除标准
- •Pregnancy
- •Refused informed consent
- •Current enrollment into another randomized controlled trial that does not allow concomitant enrollment
- •Requiring vasopressors for >12 hours before the enrollment
- •Renal failure with an imminent need for renal replacement therapy (RRT)
- •Intention to use RRT by clinical judgment despite lack of urgent clinical indication
- •AKI stage 2 and 3 at enrollment according to the KDIGO criteria
- •Prior enrollment in this study
- •Severe liver disease (Child-Pugh score >7 points)
- •Chronic kidney disease (CKD) equal to or worse than CKD stage IV (eGFR <30 mL/min/1.73 m2)
- •History of kidney transplant
- •Any condition explicitly requiring a higher or lower blood pressure target according to clinical judgment
结局指标
主要结局
A composite of mortality or AKI progression at 30 days after randomization.
时间窗: 30 days
The primary outcome will be a composite of mortality or AKI progression at 30 days after randomization. We will define AKI progression as increasing at least two AKI stages compared to the AKI stage at study enrollment. We will define and stage AKI according to the current international criteria, the KDIGO guidelines (16). We will use both creatinine and urine output criteria.
次要结局
- Quality of life at day 90.(90 days)
- Day alive and free from renal replacement therapy.(30 days)
- The need for and duration of vasopressors at 30 days after randomization(30 days)
- Days alive and outside the ICU.(30 days)
- All-cause mortality at intensive care unit discharge, hospital discharge, and 90 days after randomization.(90 days)
- Days alive and free from mechanical ventilation(30 days)
- Duration of hospital stay.(30 days)
- Major adverse kidney events at day 90.(90 days)
- Adverse events during hospital stay.(30 days)
研究者
Giovanni Landoni
MD, Full Professor
Università Vita-Salute San Raffaele